SALT LAKE CITY, Feb. 17, 2010 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (Nasdaq:MYGN) today said it will host an Investor Day from 11:00 a.m. to 2:00 p.m. Eastern on March 3, 2010, at the NASDAQ MarketSite in New York City. That same day, Myriad executives will open the NASDAQ Stock Market at 9:30 a.m.
At the meeting Myriad intends to unveil and formally launch its eighth molecular diagnostic product, PROLARIS™; discuss the commercial potential for its recently introduced OnDose™ product; and provide an update regarding its strategies for further penetrating the Woman's Healthcare market with BRACAnalysis®. Several noted guest speakers that will review the clinical benefit of the Company's products include:
- Peter Carroll, M.D., M.P.H., Professor and Chair, Urology, University of California, San Francisco
- Edward Chu, M.D., Deputy Director, Yale Cancer Center
- Greg Critchfield, M.D., Former President, Myriad Genetic Laboratories
- Richard Frieder, M.D., Medical Director, Cancer Risk Assessment and Prevention Center of Santa Monica
Additionally, Company presenters will include:
- Peter D. Meldrum, President & CEO
- Mark C. Capone, President, Myriad Genetic Laboratories
- Jerry Lanchbury, Ph.D., Chief Scientific Officer
Attendance for this event is by invitation only and space is limited. A live audio webcast of the presentations will be available to interested parties through a link on Myriad's Web site at: http://investor.myriad.com/events.cfm.
About Myriad Genetics
Myriad Genetics, Inc. is a leading molecular diagnostic company focused on developing and marketing novel predictive medicine, personalized medicine and prognostic medicine products. Myriad's news and other information are available on the Company's Web site at www.myriad.com.
The Myriad Genetics, Inc. logo is available at http://www.globenewswire.com/newsroom/prs/?pkgid=6336
Myriad, the Myriad logo, BRACAnalysis, Colaris, Colaris AP, Melaris, TheraGuide, Prezeon, OnDose, and Prolaris are trademarks or registered trademarks of Myriad Genetics, Inc. in the United States and foreign countries. OnDose is performed under patents licensed from Saladax Biomedical, Inc.
MYGN-G
This press release contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995, including statements relating to the Company's hosting of an Investor Day from 11:00 am to 2:00 pm Eastern on March 3, 2010; the unveiling and formal launch of the Company's eight molecular diagnostic product, PROLARIS; discussions with respect to the commercial potential of the Company's recently introduced OnDose product; updates regarding the Company's strategies for further penetrating the Woman's Healthcare market with BRACAnalysis; and the review of the clinical benefit of the Company's products by noted guest speakers and Company presenters. These "forward-looking statements" are based on management's current expectations of future events and are subject to a number of risks and uncertainties that could cause actual results to differ materially and adversely from those set forth in or implied by forward-looking statements. These risks and uncertainties include, but are not limited to: the risk that sales and profit margins of our existing molecular diagnostic products may decline or will not continue to increase at historical rates; the risk that we may be unable to develop or achieve commercial success for additional molecular diagnostic products in a timely manner, or at all; the risk that licenses to the technology underlying our molecular diagnostic products and any future products are terminated or cannot be maintained on satisfactory terms; risks related to delays or other problems with manufacturing our products or operating our laboratory testing facilities; risks related to public concern over our products; risks related to regulatory requirements or enforcement in the United States and foreign countries and changes in the structure of healthcare payment systems; uncertainties about our ability to obtain new corporate collaborations and acquire new technologies on satisfactory terms, if at all; the development of competing products and services; the risk that we or our licensors may be unable to protect the proprietary technologies underlying our products; the risk of patent-infringement claims or challenges of our patents; risks of new, changing and competitive technologies and regulations in the United States and internationally; and other factors discussed under the heading "Risk Factors" contained in Item 1A in our Annual Report on Form 10-K for the year ended June 30, 2009, which has been filed with the Securities and Exchange Commission, as well as any updates to those risk factors filed from time to time in our Quarterly Reports on Form 10-Q or Current Reports on Form 8-K. All information in this press release is as of the date of the release, and Myriad undertakes no duty to update this information unless required by law.